Back to Search Start Over

Compound heterozygous mutations in UBA5 causing early-onset epileptic encephalopathy in two sisters

Authors :
Brynjar O. Jensson
Reynir Arngrímsson
Daniel F. Gudbjartsson
Ragnar P. Kristjansson
Adalbjorg Jonasdottir
Gudny A. Arnadottir
Gerald Sulem
Unnur Thorsteinsdottir
Sigurjon A. Gudjonsson
Patrick Sulem
Asmundur Oddsson
Kari Stefansson
Asgeir Sigurdsson
Jona Saemundsdottir
Aslaug Jonasdottir
Gudmundur A. Thorisson
Gisli Masson
Sigurdur E. Marelsson
Olafur Th Magnusson
Stefania Benonisdottir
Source :
BMC Medical Genetics, BMC Medical Genetics, Vol 18, Iss 1, Pp 1-5 (2017)
Publication Year :
2017
Publisher :
BioMed Central, 2017.

Abstract

Background Epileptic encephalopathies are a group of childhood epilepsies that display high phenotypic and genetic heterogeneity. The recent, extensive use of next-generation sequencing has identified a large number of genes in epileptic encephalopathies, including UBA5 in which biallelic mutations were first described as pathogenic in 2016 (Colin E et al., Am J Hum Genet 99(3):695-703, 2016. Muona M et al., Am J Hum Genet 99(3):683-694, 2016). UBA5 encodes an activating enzyme for a post-translational modification mechanism known as ufmylation, and is the first gene from the ufmylation pathway that is linked to disease. Case presentation We sequenced the genomes of two sisters with early-onset epileptic encephalopathy along with their unaffected parents in an attempt to find a genetic cause for their condition. The sisters, born in 2004 and 2006, presented with infantile spasms at six months of age, which later progressed to recurrent, treatment-resistant seizures. We detected a compound heterozygous genotype in UBA5 in the sisters, a genotype not seen elsewhere in an Icelandic reference set of 30,067 individuals nor in public databases. One of the mutations, c.684G > A, is a paternally inherited exonic splicing mutation, occuring at the last nucleotide of exon 7 of UBA5. The mutation is predicted to disrupt the splice site, resulting in loss-of-function of one allele of UBA5. The second mutation is a maternally inherited missense mutation, p.Ala371Thr, previously reported as pathogenic when in compound heterozygosity with a loss-of-function mutation in UBA5 and is believed to produce a hypomorphic allele. Supportive of this, we have identified three adult Icelanders homozygous for the p.Ala371Thr mutation who show no signs of neurological disease. Conclusions We describe compound heterozygous mutations in the UBA5 gene in two sisters with early-onset epileptic encephalopathy. To our knowledge, this is the first description of mutations in UBA5 since the initial discovery that pathogenic biallelic variants in the gene cause early-onset epileptic encephalopathy. We further provide confirmatory evidence that p.Ala371Thr is a hypomorphic mutation, by presenting three adult homozygotes who show no signs of neurological disease. Electronic supplementary material The online version of this article (10.1186/s12881-017-0466-8) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
14712350
Volume :
18
Database :
OpenAIRE
Journal :
BMC Medical Genetics
Accession number :
edsair.doi.dedup.....7eb327a6eb8803b6b0d70e3ab25f2f68